AbbVie (ABBV) Tops Q4 EPS by 6c, Offers FY Guidance

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.92, $0.06 better than the analyst estimate of $2.86. Revenue for the quarter came in at $13.86 billion versus the consensus estimate of $13.73 billion.

GUIDANCE:

AbbVie sees FY2021 EPS of $12.32-$12.52, versus the consensus of $12.18.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• EU approves AbbVie's Skyrizi for children with plaque psoriasis
• AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection